Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 23, 2009

DrStockPick.com Stock Report!

**************************************************************

Maidenform Brands, Inc. (NYSE: MFB), a global branded marketer of intimate apparel, today announced that the Company will release third quarter 2009 results after the market close on November 10, 2009 with a conference call and webcast on November 11, 2009 at 8:30 a.m. Eastern Time to review these results and provide an update on the overall business.

Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Wednesday September 16, 2009, are:

**************************************************************

MVIS, Microvision, Inc.

MVIS is a global leader in innovative ultra-miniature projection display and image capture products for mobility applications

Today was the commercial introduction of the world’s first laser-based pico projector, called SHOW WX™, based on its proprietary PicoP® display engine technology.

The MVIS pico projector uses the revolutionary laser-based PicoP display engine that delivers large, colorful, bright, and vivid images that are always in focus, regardless of projection distance. The accessory product is a simple plug-n-play pico projector for people on-the-go who

...

For Immediate Release

Chicago, IL - May 8, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Auxilium Pharmaceuticals, Inc. (AUXL), Pfizer (PFE), Cognizant Technology Solutions Corp. (CTSH), Neurocrine Biosciences, Inc. (NBIX) and Coca-Cola FEMSA S.A. de C.V. (KOF).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

Auxilium a Buy at $20

Auxilium Pharmaceuticals, Inc. (AUXL) reported financial results for the first quarter 2009 on May 6, 2009. Total revenues for the first quarter were $34.7 million, an increase of 28% over the first quarter

...

Neurocrine Biosciences, Inc. (NBIX) has recently completed the entire twelve months of the Petal-602 study, which includes six months of treatment and six months follow-up.Post-treatment reviews looking to determine the impact of elagolix on bone mineral density (BMD) by dual energy X-ray Absorptiometry (DXA) show consistent results with the six month data, whereas there was no apparent effect from baseline in the elagolix treatment arms. After the twelve months, patients taking 150mg elagolix showed a mean change in BMD of +0.19% for the spine and -0.28% for the femur.Additionally, analysis of the pain data, collected utilizing the Visual Analog Scale (VAS) and the Composite Pelvic Sign and Symptoms Scale (CPSSS), revealed that the subjects report a sustained improvement of endometriosis symptoms during the six months while off medication.This is exciting data because it would seem to suggest a disease modification effect of ...

For Immediate Release

Chicago, IL - March 27, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baker Hughes, Inc. (BHI), International Business Machines Corp. (IBM), China Mobile Ltd. ADS (CHL), Neurocrine Biosciences, Inc. (NBIX) and Potash Corp. (POT).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

Baker-Hughes a Buy Up to $50

Our continued favorable view of Baker Hughes, Inc. (BHI) shares reflects the company's limited exposure to the weak North American natural gas market, its leading product-centric asset portfolio with a strong international

...

Lilac Petal Results Lie in the Interpretation of the DataOn March 25, 2009, Neurocrine Biosciences, Inc. (NBIX) reported results from the phase II -702 study, also called Lilac Petal, testing elagolix for the treatment of endometriosis.Elagolix met the primary efficacy goal for both the 150mg and 250mg on the clinically validated PGI-C scale for both overall lower PGI-C score and percent of women with a score below 2. The 150mg dose was also statistically significant for the clinically validated EHP scale.Management was also able to show a statistically significant reduction in baseline for the NRS-peak scale and dysmenorrhea (DYS).  The trial failed to show a significant reduction in NMPP or the NRS-mean scale, both which management hypothesized where measuring the same thing -- non-menstrual pelvic pain on a daily basis -- to a correlation of 0.9, and both which started with baseline ...

We have long stated that Neurocrine Biosciences Inc.’s (NBIX) stock is stuck in a tight trading range until investors get an update on both elagolix and indiplon. We got the first update in early September when the management released very positive phase II data from the PETAL study on GnRH (gonadotropin-releasing hormone) antagonist elagolix. This encouraging data for the treatment of endometriosis should lead to the signing of a major partnership for pivotal trials in 2009.

As for insomnia drug indiplon, we assume the product is eventually discontinued in the U.S.  However, with elagolix now taking center stage, Neurocrine is well positioned to outperform in 2009.  We still believe that investors can be patient while additional elagolix becomes available, but we are moving our price target to $8, from $6, on the increased likelihood that a deal for elagolix gets done in the next several months.

Investor focus has now

...